{"id":65758,"date":"2025-05-01T13:20:16","date_gmt":"2025-05-01T13:20:16","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/65758\/"},"modified":"2025-05-01T13:20:16","modified_gmt":"2025-05-01T13:20:16","slug":"eli-lilly-lly-earnings-q1-2025","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/65758\/","title":{"rendered":"Eli Lilly (LLY) earnings Q1 2025"},"content":{"rendered":"

\"Eli<\/p>\n

Eli Lilly<\/a> on Thursday reported<\/a> first-quarter revenue and earnings that topped estimates as demand for its weight loss and diabetes drugs<\/a> soared, but lowered its full-year profit guidance due to charges related to a recent cancer treatment deal.<\/p>\n

The pharmaceutical giant now expects its adjusted fiscal 2025 earnings to come in between $20.78 and $22.28 per share, down from previous guidance of $22.50 to $24 per share. Eli Lilly said the revision reflects a $1.57 billion deal charge recorded in the first quarter, which is primarily related to its acquisition of a certain oral cancer drug from Scorpion Therapeutics.<\/p>\n

The company maintained its fiscal 2025 sales guidance of $58 billion to $61 billion. Eli Lilly said the guidance reflects President Donald Trump<\/a>‘s existing tariffs as of May 1, but does not include his planned levies on pharmaceuticals imported into the U.S.<\/p>\n

In an interview with CNBC, Eli Lilly CEO Dave Ricks said the company and other drugmakers are already announcing investments in U.S. manufacturing<\/a>, which is one of the Trump administration’s stated goals of the tariffs.<\/p>\n

“I think that actually the threat of tariffs is already bringing back critical supply chains into important industries, chips and pharma,” Ricks said. “So do we need to enact [tariffs?] I’m not so sure.”<\/p>\n

He added that Eli Lilly wants to see permanent lower tax rates in the U.S., particularly 15% for domestic production. Ricks said lower taxes drove many drugmakers to manufacture in “low-tax islands like Ireland Singapore and in Switzerland, and that can come back if there’s an economic incentive.”<\/p>\n

Eli Lilly’s blockbuster diabetes treatment Mounjaro topped expectations for the first quarter, raking in $3.84 billion in revenue. That’s up a whopping 113% from the same period a year ago.<\/p>\n

The company’s weight loss drug Zepbound also beat estimates, booking $2.31 billion in sales for the quarter. That more than quadrupled the $517.4 million that the treatment brought in a year ago, when it had just entered the U.S. market.<\/p>\n

Analysts expected Mounjaro and Zepbound to generate $3.81 billion and $2.28 billion in sales, respectively, according to estimates from StreetAccount.<\/p>\n

Shares of Eli Lilly fell 4% on Thursday. That came after CVS Health<\/a> on Thursday said its pharmacy benefit manager would make Novo Nordisk’s<\/a> Wegovy the preferred weight loss medication on its main formularies instead of Zepbound. <\/p>\n

Here’s what Eli Lilly reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG:\u00a0<\/p>\n